Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection.

作者: Salih Ibrahem , Rashmi Seth , Brendan O’Sullivan , Wakkas Fadhil , Philippe Taniere

DOI: 10.1111/J.1365-2613.2010.00733.X

关键词:

摘要: Mutation detection is important in cancer management. Several methods are available of which high resolution melting (HRM) analysis and pyrosequencing the most versatile. We undertook a comparative these techniques. The are: To compare limit (LOD), mutations KRAS (codon 12/13 hotspot) BRAF (V600E were tested. DNA mixtures containing mutant alleles at frequency around 25%/12.5%/6%/3%/ 1.5%/0.8% analysed. mutation detection, 22 samples (nine quality from cell lines, 13 low formalin-fixed paraffin-embedded tissue) tested for three hotspots (codons 12/13, 61 146) two exon 11). HRM (codon12/13) (V600E) showed that 3% 1.5% respectively could be reliably detected whilst 6% each case. Of 110 tests performed on samples, 109 cases gave identical results. Two had previously been called as wild type by direct Sanger sequencing but found to both pyrosequencing. Both can detect small numbers although has lower detection. suitable use more sensitive than sequencing.

参考文章(26)
M. Ilyas, J. Straub, I.P.M. Tomlinson, W.F. Bodmer, Genetic pathways in colorectal and other cancers European Journal of Cancer. ,vol. 35, pp. 335- 351 ,(1999) , 10.1016/S0959-8049(98)00431-6
Avichai Shimoni, Asaf Vivante, Luba Trakhtenbrot, Gideon Rechavi, Ninette Amariglio, Ron Loewenthal, Arnon Nagler, Yoram Cohen, A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leukemia Research. ,vol. 32, pp. 421- 427 ,(2008) , 10.1016/J.LEUKRES.2007.07.003
Carl T Wittwer, Gudrun H Reed, Cameron N Gundry, Joshua G Vandersteen, Robert J Pryor, High-Resolution Genotyping by Amplicon Melting Analysis Using LCGreen Clinical Chemistry. ,vol. 49, pp. 853- 860 ,(2003) , 10.1373/49.6.853
D. Williams Parsons, Tian-Li Wang, Yardena Samuels, Alberto Bardelli, Jordan M. Cummins, Laura DeLong, Natalie Silliman, Janine Ptak, Steve Szabo, James K. V. Willson, Sanford Markowitz, Kenneth W. Kinzler, Bert Vogelstein, Christoph Lengauer, Victor E. Velculescu, Mutations in a signalling pathway Nature. ,vol. 436, pp. 792- 792 ,(2005) , 10.1038/436792A
Hongdo Do, Michael Krypuy, Paul L Mitchell, Stephen B Fox, Alexander Dobrovic, High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies BMC Cancer. ,vol. 8, pp. 142- 142 ,(2008) , 10.1186/1471-2407-8-142
Sandrine Dufort, Marie-Jeanne Richard, Florence de Fraipont, Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Analytical Biochemistry. ,vol. 391, pp. 166- 168 ,(2009) , 10.1016/J.AB.2009.05.027
Deborah Packham, Robyn L. Ward, Vita Ap Lin, Nicholas J. Hawkins, Megan P. Hitchins, Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagnostic Molecular Pathology. ,vol. 18, pp. 62- 71 ,(2009) , 10.1097/PDM.0B013E318182AF52
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Annals of Oncology. ,vol. 19, pp. 508- 515 ,(2008) , 10.1093/ANNONC/MDM496
Fréderic Bibeau, Marie-Danièle Diebold, Philippe Rougier, Michel Ducreux, Gorana Tomasic, Jean-François Emile, Frédérique Penault-Llorca, Pierre Laurent-Puig, Astrid Lièvre, Jean-Baptiste Bachet, Valérie Boige, Anne Cayre, Delphine Le Corre, Emmanuel Buc, Marc Ychou, Olivier Bouché, Bruno Landi, Christophe Louvet, Thierry André, KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab Journal of Clinical Oncology. ,vol. 26, pp. 374- 379 ,(2008) , 10.1200/JCO.2007.12.5906